# Clinical Spectrum of Cutaneous, Ocular, and Hair Manifestations in Patients With Inborn Errors of Immunity: Insights From a Single Center in Turkey

**Authors:** Burcu Cil Yılmaz, Sibel Kaplan Sarikavak, Sezin Naiboglu, Gulsah Kalay, Erkan Cakmak, Ozge Turkyilmaz Ucar, Selami Ulas, Nermin Kapci, Pinar Gokmirza, Cigdem Aydogmus

PMC · DOI: 10.1002/iid3.70384 · Immunity, Inflammation and Disease · 2026-02-25

## TL;DR

This study shows that skin, eye, and hair issues often appear early in immune disorders and can help with diagnosis.

## Contribution

The study provides insights into the clinical value of cutaneous, ocular, and hair manifestations in diagnosing inborn errors of immunity.

## Key findings

- Cutaneous, ocular, and/or hair manifestations were present in 51.3% of patients with IEI.
- Eczema was most common in hyper-IgE syndrome, while skin infections were frequent in phagocytic and innate immunity defects.
- Ocular and hair abnormalities were observed across multiple IEI subgroups, supporting their diagnostic relevance.

## Abstract

Inborn errors of immunity (IEI), previously referred to as primary immunodeficiencies, are a heterogeneous group of genetic disorders affecting immune development and function. While once considered rare, IEIs are increasingly recognized, particularly in regions with high consanguinity rates. Cutaneous manifestations, as well as ocular and hair abnormalities, may provide early and clinically relevant diagnostic clues. This study aimed to assess the prevalence, types, and diagnostic value of cutaneous, ocular and hair manifestations in patients with IEI.

A total of 386 patients with confirmed IEI, classified according to the 2024 IUIS criteria, were retrospectively analyzed. Cutaneous, ocular (e.g., conjunctivitis, keratitis, scleral telangiectasia), and hair manifestations (e.g., alopecia areata, pigmentary abnormalities) were systematically reviewed from medical records. Skin findings were categorized as infectious, immune‐allergic (eczema, alopecia areata, urticaria, erythroderma), disease‐specific, or other.

Cutaneous, ocular, and/or hair manifestations were identified in 198 patients (51.3%), with 59.1% present at diagnosis. Infectious manifestations were the most common (71.8%), followed by immune‐allergic findings (34.8%), including eczema (30.3%), and disease‐specific manifestations (17.7%). Ocular findings were observed in 15.7% of patients, while hair abnormalities were present in 4.04%. Skin infections were predominantly bacterial (53.1%) and were most frequent in phagocytic and innate immunity defects. Eczema was most frequent in hyper‐IgE syndrome (85.8%), while non‐eczematous allergic findings were most common in immune dysregulation. Ocular involvement, including viral retinitis and scleral telangiectasia, and hair abnormalities, such as syndromic hair shaft defects and alopecia areata, were observed across multiple IEI subgroups.

Cutaneous, ocular, and hair abnormalities are frequent in IEI and may support early diagnosis. Recognition of recurrent, atypical, or treatment‐resistant skin, eye, or hair findings should prompt immunological evaluation, particularly in pediatric patients.

•Cutaneous, ocular, hair manifestations represent clinically meaningful and often early indicators of IEI.•This study highlights the diagnostic value of infectious skin lesions, eczema, disease‐specific cutaneous findings, and selected ocular and hair abnormalities across different IEI categories.•Integrating dermatologic and ophthalmologic assessment into routine clinical evaluation may facilitate earlier recognition of IEI and support timely immunologic work‐up and when indicated, molecular testing, particularly in pediatric populations.

Cutaneous, ocular, hair manifestations represent clinically meaningful and often early indicators of IEI.

This study highlights the diagnostic value of infectious skin lesions, eczema, disease‐specific cutaneous findings, and selected ocular and hair abnormalities across different IEI categories.

Integrating dermatologic and ophthalmologic assessment into routine clinical evaluation may facilitate earlier recognition of IEI and support timely immunologic work‐up and when indicated, molecular testing, particularly in pediatric populations.

## Linked entities

- **Diseases:** hyper-IgE syndrome (MONDO:0018037)

## Full-text entities

- **Genes:** IL6ST (interleukin 6 cytokine family signal transducer) [NCBI Gene 3572] {aka CD130, CDW130, GP130, HIES4, HIES4A, HIES4B}, IL10RA (interleukin 10 receptor subunit alpha) [NCBI Gene 3587] {aka CD210, CD210a, CDW210A, HIL-10R, IL-10R1, IL10R}, IL12RB1 (interleukin 12 receptor subunit beta 1) [NCBI Gene 3594] {aka CD212, IL-12R-BETA1, IL12RB, IMD30}, SPINK5 (serine peptidase inhibitor Kazal type 5) [NCBI Gene 11005] {aka LEKTI, LETKI, NETS, NS, VAKTI}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, DCLRE1C (DNA cross-link repair 1C) [NCBI Gene 64421] {aka A-SCID, DCLREC1C, RS-SCID, SCIDA, SNM1C}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SP110 (SP110 nuclear body protein) [NCBI Gene 3431] {aka IFI41, IFI75, IPR1, VODI}, TNFRSF9 (TNF receptor superfamily member 9) [NCBI Gene 3604] {aka 4-1BB, CD137, CDw137, ILA, IMD109}, MALT1 (MALT1 paracaspase) [NCBI Gene 10892] {aka IMD12, MLT, MLT1, PCASP1}, IKBKG (inhibitor of nuclear factor kappa B kinase regulatory subunit gamma) [NCBI Gene 8517] {aka AMCBX1, EDAID1, FIP-3, FIP3, Fip3p, IKK-gamma}, AIRE (autoimmune regulator) [NCBI Gene 326] {aka AIRE1, APECED, APS1, APSI, PGA1}, USB1 (U6 snRNA biogenesis phosphodiesterase 1) [NCBI Gene 79650] {aka C16orf57, HVSL1, Mpn1, PN, hMpn1, hUsb1}, RAG2 (recombination activating 2) [NCBI Gene 5897] {aka RAG-2}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, TNFRSF13B (TNF receptor superfamily member 13B) [NCBI Gene 23495] {aka CD267, CVID, CVID2, IGAD2, RYZN, TACI}, RAG1 (recombination activating 1) [NCBI Gene 5896] {aka RAG-1, RNF74}, LYST (lysosomal trafficking regulator) [NCBI Gene 1130] {aka CHS, CHS1, Mauve}, STK4 (serine/threonine kinase 4) [NCBI Gene 6789] {aka KRS2, MST1, YSK3}, YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) [NCBI Gene 7529] {aka GW128, HEL-S-1, HS1, KCIP-1, YWHAA}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, NHEJ1 (non-homologous end joining factor 1) [NCBI Gene 79840] {aka IMD124, MCOPCB13, XLF}, RAB27A (RAB27A, member RAS oncogene family) [NCBI Gene 5873] {aka GS2, HsT18676, RAB27, RAM}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}, PLCG2 (phospholipase C gamma 2) [NCBI Gene 5336] {aka APLAID, FCAS3, PLC-IV, PLC-gamma-2}, FCHO1 (FCH and mu domain containing endocytic adaptor 1) [NCBI Gene 23149] {aka IMD76}, GATA2 (GATA binding protein 2) [NCBI Gene 2624] {aka DCML, IMD21, MONOMAC, NFE1B}, ARPC1B (actin related protein 2/3 complex subunit 1B) [NCBI Gene 10095] {aka ARC41, IMD71, PLTEID, p40-ARC, p41-ARC}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, JAK3 (Janus kinase 3) [NCBI Gene 3718] {aka JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, DOCK8 (dedicator of cytokinesis 8) [NCBI Gene 81704] {aka HEL-205, HIES2, MRD2, ZIR8}, CASP10 (caspase 10) [NCBI Gene 843] {aka ALPS2, FLICE-2, FLICE2, MCH4}, ADA (adenosine deaminase) [NCBI Gene 100] {aka ADA1}, TNFSF9 (TNF superfamily member 9) [NCBI Gene 8744] {aka 4-1BB-L, CD137L, TNLG5A}, IL2RG (interleukin 2 receptor subunit gamma) [NCBI Gene 3561] {aka CD132, CIDX, IL-2RG, IMD4, P64, SCIDX}, SERPING1 (serpin family G member 1) [NCBI Gene 710] {aka C1IN, C1INH, C1NH, HAE1, HAE2}, LRBA (LPS responsive beige-like anchor protein) [NCBI Gene 987] {aka BGL, CDC4L, CVID8, LAB300, LBA, uc.147}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, ELANE (elastase, neutrophil expressed) [NCBI Gene 1991] {aka ELA2, GE, HLE, HNE, NE, PMN-E}, BTK (Bruton tyrosine kinase) [NCBI Gene 695] {aka AGMX1, AT, ATK, BPK, IGHD3, IMD1}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, PGM3 (phosphoglucomutase 3) [NCBI Gene 5238] {aka AGM1, IMD23, PAGM, PGM 3}, IRAK4 (interleukin 1 receptor associated kinase 4) [NCBI Gene 51135] {aka IMD67, IPD1, IRAK-4, NY-REN-64, REN64}, SRP54 (signal recognition particle 54) [NCBI Gene 6729] {aka SCN8}, RBCK1 (RANBP2-type and C3HC4-type zinc finger containing 1) [NCBI Gene 10616] {aka C20orf18, HOIL-1, HOIL1, PBMEI, PGBM1, RBCK2}, NCF1 (neutrophil cytosolic factor 1) [NCBI Gene 653361] {aka CGD1, NCF-1, NCF-47K, NCF1A, NOXO2, SH3PXD1A}, HAX1 (HCLS1 associated protein X-1) [NCBI Gene 10456] {aka HCLSBP1, HS1BP1, SCN3}
- **Diseases:** Enteropathy (MESH:C538273), Autoinflammatory disorders (MESH:D056660), human papillomavirus infection (MESH:D030361), Griscelli syndrome (MESH:C537301), genetic disorders (MESH:D030342), Primary immunodeficiencies (MESH:D000081207), Combined Immunodeficiency (MESH:D053632), bone marrow failure (MESH:D000080983), trichorrhexis nodosa (MESH:C536556), AIRE deficiency (MESH:D016884), Ecthyma gangrenosum (MESH:D004473), infectious skin lesions (MESH:D012874), CGD (MESH:D006105), alopecia (MESH:D000505), IGLL1 defects (MESH:D000361), autoimmunity (MESH:D001327), CMV (MESH:D003586), intrinsic (MESH:D020919), CHS (MESH:D002609), urticaria (MESH:D014581), viremia (MESH:D014766), Signal Transducer and Activator of Transcription 3 Deficiency (MESH:C566796), Molluscum Contagiosum (MESH:D008976), autoimmune-mediated (MESH:C567355), Wiskott-Aldrich Syndrome (MESH:D014923), pigmentary abnormalities (MESH:C536859), Hair and eye abnormalities (MESH:D005124), C1 esterase inhibitor deficiency (MESH:D054179), T-cell lymphopenia (MESH:D008231), malignancy (MESH:D009369), Susceptibility to (MESH:C562694), immunoglobulin isotype deficiencies (MESH:D004406), CMC (MESH:D002178), MSMD (MESH:C564468), IgA deficiency (MESH:D017098), Perianal abscess (MESH:D000038), granulomatous inflammation (MESH:D007249), T-cell defects (MESH:C536722), congenital anomalies (MESH:D000013), EBV (MESH:D020031), CVID (MESH:D017074), Telangiectasia (MESH:D013684), immune impairment (MESH:D020274), warts (MESH:D014860), PNP deficiency (MESH:C562587), Granulomatous skin lesions (MESH:D012871), hyperpigmentation (MESH:D017495), ED-ID (MESH:C537985), Immune Dysregulation (OMIM:614878), Fungal infections (MESH:D009181), Psoriasiform erythroderma (MESH:D003873), fistula (MESH:D005402), SCID (MESH:D016511), Alopecia areata (MESH:D000506), HIES (MESH:D007589), Dedicator of Cytokinesis 8 Deficiency (OMIM:615401), STK4 deficiency (OMIM:614868), Infectious (MESH:D003141), invasive (MESH:D009361), IPEX (MESH:C580192)
- **Species:** Pseudomonas aeruginosa (species) [taxon 287], Human papillomavirus (species) [taxon 10566], Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12933409/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12933409/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12933409/full.md

---
Source: https://tomesphere.com/paper/PMC12933409